318 related articles for article (PubMed ID: 36295543)
1. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.
Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Lengyel C; Kempler P; Wittmann I
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295543
[TBL] [Abstract][Full Text] [Related]
2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
[TBL] [Abstract][Full Text] [Related]
4. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
[TBL] [Abstract][Full Text] [Related]
5. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
6. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV
Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049
[TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
12. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.
Bongaerts B; Kollhorst B; Kuss O; Pigeot I; Rathmann W
Exp Clin Endocrinol Diabetes; 2022 Sep; 130(9):587-595. PubMed ID: 34942670
[TBL] [Abstract][Full Text] [Related]
13. Trends in add-on medications following metformin monotherapy for type 2 diabetes.
Swart EC; Neilson LM; Munshi KD; Peasah SK; Henderson R; Good CB
J Manag Care Spec Pharm; 2022 Nov; 28(11):1253-1259. PubMed ID: 36282929
[No Abstract] [Full Text] [Related]
14. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
15. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Volke V; Katus U; Johannson A; Toompere K; Heinla K; Rünkorg K; Uusküla A
BMC Endocr Disord; 2022 Oct; 22(1):251. PubMed ID: 36261824
[TBL] [Abstract][Full Text] [Related]
17. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
18. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of anti-diabetic medications as add-on to metformin in type 2 diabetes mellitus from a real-world database.
Ono R; Ogami C; Hasegawa C; To H; Matsumoto Y; Tsuji Y
BMC Pharmacol Toxicol; 2023 Dec; 24(1):75. PubMed ID: 38066653
[TBL] [Abstract][Full Text] [Related]
20. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
